Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
Authors:
Open Access
- 18 September 2019
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (9) , 1527-1535
Abstract
Background: Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory.Methods: Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was overall survival (OS). The key secondary outcomes were progression-free survival (PFS) and safety. Patients previously treated with any agent targeting T cell costimulation or immune checkpoints were excluded.Results: The study included 77 patients (a PD-1 inhibitor plus chemotherapy,n = 38; PD-1 inhibitor monotherapy,n = 20; chemotherapy alone,n = 19). The median OS was 14.9 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 4.1 months with PD-1 inhibitor monotherapy (HR 0.37, 95% CI 0.17–0.80,P = 0.001) and the 6.0 months with chemotherapy alone (HR 0.63, 95% CI 0.42–0.94,P = 0.011). The median PFS was 5.1 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 2.2 months with PD-1 inhibitor monotherapy (HR 0.59, 95% CI 0.31–1.10,P = 0.014) and the 2.4 months with chemotherapy alone (HR 0.61, 95% CI 0.45–0.83,P = 0.003). Grade 3 or 4 treatment-related adverse events were similar between the anti-PD-1 combination group and the chemotherapy alone group (34.2% and 36.8%, respectively).Conclusions: Anti-PD-1 therapy plus chemotherapy is an effective and tolerable approach for advanced BTC.Keywords
Funding Information
- National Natural Science Foundation of China (81402552, 81672996)
This publication has 36 references indexed in Scilit:
- Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0Journal of the American Academy of Dermatology, 2012
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceJournal of Clinical Investigation, 2011
- Risk factors for cholangiocarcinomaHepatology, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Epidemiology of biliary tract cancers: an updateAnnals of Oncology, 2008
- Systemic Therapy for Biliary Tract CancersThe Oncologist, 2008
- CholangiocarcinomaAnnals of Surgery, 2007
- Biliary Tract CancersNew England Journal of Medicine, 1999